Search results for "acetate"

showing 10 items of 756 documents

Polymorphonuclear leukocyte integrin pattern, at baseline and after activation, in type 2 diabetic subjects with macrovascular complications.

2003

In vascular atherosclerotic disease and in diabetes mellitus few studies have evaluated the polymorphonuclear leukocyte (PMN) adhesion molecule pattern. In this study we examined the PMN integrin expression at baseline and after activation in controls and type 2 diabetic subjects with macrovascular complications (MVC). We enrolled 21 subjects with type 2 diabetes mellitus and macrovascular complications, localized in peripheral, coronary and cerebral sites. The patients had peripheral occlusive arterial disease, chronic cerebrovascular disease or coronary heart disease. We evaluated the expression of some PMN integrins (CD11a, CD11b, CD11c, CD18), using flow cytofluorimetry, at baseline and…

Malemedicine.medical_specialtyIntegrinsNeutrophilsEndocrinology Diabetes and MetabolismIntegrinCD11cchemical and pharmacologic phenomenaCD18CD11aEndocrinologyInternal medicineDiabetes mellitusInternal MedicinemedicineHumansCD11a AntigenAgedCD11b AntigenbiologyCell adhesion moleculebusiness.industryType 2 Diabetes Mellitushemic and immune systemsGeneral MedicineMiddle Agedmedicine.diseaseCD11c AntigenEndocrinologyIntegrin alpha MDiabetes Mellitus Type 2CD18 Antigensbiology.proteinTetradecanoylphorbol AcetateFemalebusinessDiabetic AngiopathiesActa diabetologica
researchProduct

Gender-dependent behavioural impairment and brain metabolites in young adult rats after short term exposure to lead acetate

2012

We investigated the behavioural effects of short-term lead (Pb) exposure in adult rats producing blood Pb concentration (<10. μg/dL) below those associated with neurological impairment in occupationally exposed individuals. In order to assess gender differences, we performed parallel behavioural experiments in male and female rats. Exposure to Pb acetate (50. mg/L in drinking water) for 30-45 days induced behavioural alterations consisting in hyperactivity in a novel environment and impairment of spatial memory. These effects were observed only in male rats. Object recognition, motor coordination were unaffected by Pb exposure. Magnetic resonance spectroscopy allows . in vivo assessment of …

Malemedicine.medical_specialtyMagnetic Resonance SpectroscopyMetaboliteGlutamineCentral nervous systemHippocampusGlutamic AcidMotor ActivityToxicologyCreatineCholinechemistry.chemical_compoundSex FactorsMemoryInternal medicinemedicineOrganometallic CompoundsCholineAnimalsRats WistarMaze LearningBrain ChemistryAspartic AcidGlutamate receptorRecognition PsychologyGeneral MedicineCreatineMotor coordinationRatsEndocrinologymedicine.anatomical_structurechemistryLead acetateFemaleInositolPsychomotor Performance
researchProduct

Lower Urinary Tract Symptoms: What's New in Medical Treatment?

2018

Abstract Context Pharmacological treatment is a cornerstone in the management of patients with lower urinary tract symptoms (LUTS). Objective To review emerging evidence in the medical treatment of LUTS. Evidence acquisition An Embase/Pubmed-based literature search was conducted in December 2017, screening for randomized controlled trials (RCTs), prospective and retrospective series, animal model studies, and reviews on medical treatment of LUTS. Evidence synthesis The main medical innovation in recent years in overactive bladder (OAB) has been the approval of the first β 3 -adrenoceptor agonists (mirabegron) and intradetrusor onabotulinum toxin A, while several other drugs such as antiepil…

Malemedicine.medical_specialtyReceptors VasopressinUrologyUrinary Bladder030232 urology & nephrologyUrologyProstatic HyperplasiaUrinary incontinenceAdrenergic beta-3 Receptor Agonistsurologic and male genital diseases03 medical and health sciences0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsmedicineDesmopressin AcetateNocturiaHumansDeamino Arginine VasopressinProspective StudiesBotulinum Toxins Type ADesmopressinRandomized Controlled Trials as TopicRetrospective StudiesUrinary bladderbusiness.industryUrinary Bladder OveractiveAntidiuretic AgentsPhosphodiesterase 5 Inhibitorsmedicine.diseasefemale genital diseases and pregnancy complicationsThiazolesmedicine.anatomical_structureOveractive bladderClinical Trials Phase III as Topic030220 oncology & carcinogenesisModels AnimalAcetanilidesFemaleNocturiamedicine.symptomMirabegronbusinessmedicine.drugEuropean urology focus
researchProduct

Ethopharmacological studies on the effects of antihormones on rodent agonistic behavior with especial emphasis on progesterone.

1991

The effects of a range of antiandrogens and antiestrogens on conflict behaviors in laboratory rats and mice are reassessed in the light of recent studies applying ethophamacological analyses (recording the full spectrum of behaviors) to such investigations. It is argued that any antihostility properties of the antiandrogen cyproterone acetate are largely a consequence of indirect actions on odor communication, whereas antiestrogens (e.g., tamoxifen and CI 680) seem to have more fundamental motivational effects in addition to communicatory actions. A detailed example of the approach is provided in which progesterone (which can be antiandrogenic) is given to rats paired in different ways. The…

Malemedicine.medical_specialtyRodentLightmedicine.drug_classAntiandrogensCognitive NeuroscienceAntiandrogenStyrenesBehavioral Neurosciencechemistry.chemical_compoundMiceInternal medicinebiology.animalmedicineAgonistic behaviourAnimalsInterpersonal RelationsCyproteroneCyproterone AcetateProgesteronebiologyBody WeightEstrogen AntagonistsCyproterone acetateEstrogen AntagonistsAndrogen AntagonistsOrgan SizeRatsTamoxifenNeuropsychology and Physiological PsychologyEndocrinologychemistryCyproteroneFemalePsychologyhormones hormone substitutes and hormone antagonistsAfter treatmentAgonistic Behaviormedicine.drugNeuroscience and biobehavioral reviews
researchProduct

The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prosta…

2017

Two new drugs, the CYP17 inhibitor abiraterone acetate and the androgen receptor (AR) antagonist enzalutamide, have recently shown to prolong OS prior chemotherapy or in docetaxel treated mCRPC patients, using steroidal therapy or placebo as control group. Updated analyses underlined the role of these new agents on two prostate-specific endpoints as radiographic progression-free survival (rPFS) and time to first skeletal-related event (tSRE). On the basis of these reports, we made an indirect comparison between abiraterone and enzalutamide. We obtained a clinically but not significant difference favouring enzalutamide over abiraterone in terms of rPFS (HR 0.48, 95% CI 0.22–1.02). No signi…

Malemedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentUrologyAbiraterone AcetateBone NeoplasmsAbiraterone; Enzalutamide; mCRPC; rPFS; tSRE; Hematology; Oncology; Geriatrics and GerontologyPlaceboDisease-Free Survivallaw.invention03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineRandomized controlled triallawNitrilesPhenylthiohydantoinEnzalutamideAndrogen Receptor AntagonistsMedicineEnzalutamideCytochrome P-450 Enzyme InhibitorsHumans030212 general & internal medicineProgression-free survivalAbirateronetSRERandomized Controlled Trials as TopicChemotherapybusiness.industryAbiraterone acetateHematologymCRPCmedicine.diseaseProstatic Neoplasms Castration-ResistantTreatment OutcomechemistryDocetaxelrPFSOncology030220 oncology & carcinogenesisBenzamidesDisease ProgressionGeriatrics and Gerontologybusinessmedicine.drugCritical reviews in oncology/hematology
researchProduct

Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial.

1980

Summary— Forty-two patients with previously untreated T3/4 N1-4 MO/1 prostatic adenocarcinoma were treated with either cyproterone acetate (n=21; 300 mg intramuscularly per week) or oestradiol undecylate (n=21; 100 mg intramuscularly per month) after extensive staging which included open skeletal biopsy and pelvic lymphadenectomy in some cases. Subjective and objective parameters as well as signs of drug toxicity were recorded regularly. Evaluation after 6 months showed cyproterone acetate to be more effective in the following respects: (1) the significantly different castration effect as judged by plasma testosterone, (2) the objective voiding pattern and tumour response, with regression o…

Malemedicine.medical_specialtyTime FactorsUrologyUrologyAdenocarcinomachemistry.chemical_compoundRandom AllocationBiopsymedicineHumansCyproteronePelvic lymphadenectomyDrug toxicityTestosteroneAgedClinical Trials as Topicmedicine.diagnostic_testEstradiolProstatic adenocarcinomabusiness.industryCyproterone acetateCancerProstatic NeoplasmsMiddle Agedmedicine.diseaseSurgeryCastrationchemistrybusinessBritish journal of urology
researchProduct

Testosterone metabolism in benign prostatic hypertrophy: in vivo studies of gestonorone caproate and cyproterone acetate.

1976

Summary 18 patients with obstructive benign prostatic hypertrophy were studied. A 5-day treatment with gestonorone caproate (200 mg daily and 200 mg on alternate days) and cyproterone acetate (300 mg daily) suppressed the plasma LH and serum LH levels. Subsequently, H3-testosterone was injected intravenously and its elimination from plasma and uptake and metabolism in the BPH tissue studied. The elimination of total radioactivity and H3-testosterone from plasma was not altered after the 3 treatment regimens as compared to the control group. The uptake of total radioactivity into BPH tissue and its intraprostatic metabolism particularly to dihydrotestosterone was significantly suppressed in …

Malemedicine.medical_specialtyUrologyProstatic HyperplasiaMuscle hypertrophychemistry.chemical_compoundIn vivoInternal medicinemedicineHumansTestosteroneCyproteroneTestosteroneGestonorone caproateAgedClinical Trials as TopicTreatment regimenbusiness.industryProstateCyproterone acetateMetabolismLuteinizing HormoneMiddle AgedEndocrinologychemistryDihydrotestosteronebusinessGestonorone Caproatemedicine.drugBritish journal of urology
researchProduct

Action of metyrapone on the redox state of free nicotinamide-adenine dinucleotide and on oxygen consumption of perfused rat livers and isolated mitoc…

1971

Metyrapone [2-methyl-1,2-bis-(3-pyridyl)-1-propanone] in a concentration of 5 mM increased the lactate/pyruvate ratio and theΒ-hydroxybutyrate/ acetoacetate ratio in the perfusion fluid of the isolated rat liver by a factor of 6 indicating a considerable shift in the ratio of free [NAD]/[NADH] in both the cytoplasmic and the mitochondrial compartment. Oxygen uptake of the isolated liver was decreased to about one half. The onset of the inhibitory effect on the respiration of the isolated organ was immediate. The inhibition lasted for at least 1 h.

Malemedicine.medical_specialtychemistry.chemical_elementHydroxybutyratesMitochondria LiverNicotinamide adenine dinucleotideIn Vitro TechniquesOxygenRedoxAcetoacetatesElectron Transportchemistry.chemical_compoundHydroxybutyrate DehydrogenaseOxygen ConsumptionInternal medicineRespirationmedicineAnimalsPyruvatesPharmacologyMetyraponeChemistryGeneral MedicineCompartment (chemistry)MetyraponeNADRatsPerfusionKineticsEndocrinologyBiochemistryLiverCytoplasmSpectrophotometryDepression ChemicalLactatesNAD+ kinasemedicine.drugFerrocyanidesPolarographyNaunyn-Schmiedebergs Archiv fur Pharmakologie
researchProduct

In vivo studies on the antiandrogenic effects of cimetidine versus cyproterone acetate in rats

1981

To investigate the antiandrogenic action of cimetidine in vivo, prostatic androgen uptake and metabolism, spermatogenesis, morphology of the prostate and testes, and plasma hormone levels were studied using Sprague-Dawley rats, and the results were compared with the effects of cyproterone acetate or castration. Cimetidine and cyproterone acetate caused significant reduction in the weights of the ventral prostate and testes. The changes of ventral prostate were accompanied by a dose-related epithelial atrophy. No adverse effect on spermatogenesis was observed after treatment with cimetidine at daily doses of 50 mg/kg or cyproterone acetate of 10 mg/kg. Although cimetidine treatment induced a…

Malemedicine.medical_specialtymedicine.drug_classUrologyPharmacologyGuanidineschemistry.chemical_compoundIn vivoProstateInternal medicineTestismedicineAnimalsTestosteroneCastrationCyproteroneCimetidineCyproterone AcetateSpermatogenesisTestosteroneProstateCyproterone acetateAndrogen AntagonistsRats Inbred StrainsOrgan SizeLuteinizing HormoneAndrogenRatsCastrationEndocrinologymedicine.anatomical_structureOncologychemistryFollicle Stimulating HormoneCimetidineSpermatogenesismedicine.drugThe Prostate
researchProduct

Calcium-enriched bread for treatment of uremic hyperphosphatemia

2004

Abstract Objective To assess phosphate-binding efficacy of a new food product, bread with unusually high calcium content (Ca-bread). Design and setting A randomized parallel group trial in the university hospital outpatient dialysis unit. Patients Fifty-three randomly selected uremic patients who met the following inclusion criteria: (1) required maintenance hemodialysis treatment, (2) were not to receive vitamin D throughout the study, (3) were nondiabetic, and (4) were diagnosed with hyperphosphatemia. Intervention Fifty-three patients were randomized into 2 groups: control group (n = 26), which received calcium acetate as a phosphate binder throughout the study, and Ca-bread group (n = 2…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentElemental calciumMedicine (miscellaneous)chemistry.chemical_elementAcetatesCalciumPhosphatesHyperphosphatemiachemistry.chemical_compoundAnimal scienceRenal DialysismedicineVitamin D and neurologyHumansUremiaNutrition and Dieteticsbusiness.industrydigestive oral and skin physiologyfood and beveragesBreadCalcium CompoundsMiddle Agedmedicine.diseasePhosphateDiet RecordsSurgeryPhosphate binderCalcium DietarychemistryNephrologyFood FortifiedCalcium CompoundsPatient CompliancePhosphorus DietaryCalciumFemaleHemodialysisbusinessJournal of Renal Nutrition
researchProduct